Persistent URL of this record https://hdl.handle.net/1887/3279508
Documents
-
- Download
- 111972271_submittedVersion_bfa41bc4dfeca7f7fae
- Publisher's Version
- open access
- Full text at publishers site
In Collections
This item can be found in the following collections:
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19) an investigator-initiated, randomised, open-label, phase 2 trial
- All authors
- Gooijer, C.J. de; Noort, V. van der; Stigt, J.A.; Baas, P.; Biesma, B.; Cornelissen, R.; Walree, N. van; Heemst, R.C. van; Youssef-El Soud, M.; Groen, H.J.M.; Staal-van den Brekel, A.J.; Buikhuisen, W.A.; Bootsma, G.P.; Dammeijer, F.; Tinteren, H. van; Lalezari, F.; Aerts, J.G.; Burgers, J.A.; NVALT19 Study Grp
- Date
- 2023-03-01
- Journal
- The Lancet Respiratory Medicine
- Volume
- 9
- Issue
- 6
- Pages
- 585 - 592